NCT07489599尚未招募1 期
A Randomized, Double-Blind, Placebo-Controlled, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single, Subcutaneous, Ascending Doses of QLH2405 Injection in Healthy Participants and Participants With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 入组人数
- 68
- 主要终点
- Adverse Events (AEs)
研究概览
简要总结
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of QLH2405 injection in healthy participants and participants with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild Alzheimer's disease.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 85 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •for Part A:
- •Voluntarily participate and sign the informed consent.
- •Male or female, aged 18 to 65 years (inclusive).
- •Healthy status as confirmed by medical evaluation.
- •Body mass index (BMI) of 19-28 kg/m² (inclusive).
- •Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.
- •Inclusion Criteria for Part B:
- •Voluntarily participate and sign the informed consent, able to communicate well with the investigator and complete the trial per protocol.
- •Male or female, aged 50 to 85 years (inclusive).
- •A diagnosis of mild MCI due to AD or mild AD according to the National Institute on Aging and the Alzheimer's Association (NIA-AA) criteria.
- •Has subjective cognitive and memory decline for ≥6 months.
- •Confirmation of Alzheimer's disease pathological changes by amyloid PET (Aβ-PET) scan.
- •Has one (or more) reliable study partner (s)/adult caregiver(s) can accompany the participant to all visits.
- •Agree to use effective contraception and have no plans for sperm/egg donation or pregnancy from ICF signing until 9 months post-dose.
排除标准
- •for Part A:
- •History of significant diseases, or any existing disease may affect the study or pose an unacceptable risk to the participant.
- •Positive for HBsAg, HIV-Ab, Treponema pallidum antibody, or HCV-Ab.
- •History of blood donation, significant blood loss (total volume ≥400 mL), or blood transfusion within 3 months prior to screening.
- •History of alcohol abuse within 1 year prior to screening; or positive alcohol breath test.
- •History of drug abuse and/or substance abuse; or positive drug screening.
- •Participation in any drug or medical device clinical trial within 3 months prior to screening.
- •Pregnant or lactating women, or women of childbearing potential with a positiveβ-hCG test.
- •Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
- •Exclusion Criteria for Part B:
- •Cognitive impairment or dementia caused by any disease other than AD.
- •History of stroke within 6 months prior to screening, or imaging evidence of clinically significant central nervous system diseases.
- •History of epileptic seizures or epileptiform abnormalities on EEG within 6 months prior to screening.
- •Unstable or severe diseases within 6 months prior to screening that, in the investigator's judgment, make the participant unsuitable for study participation.
- •eGFR <60 mL/min/1.73 m².
- •AST or ALT >3 × upper limit of normal (ULN), or total bilirubin >2 × ULN.
- •Current use or anticipated need during the study period for any medication prohibited by the study protocol.
- •Any other condition that, in the investigator's judgment, makes the participant unsuitable for participation in this study.
结局指标
主要结局
Adverse Events (AEs)
时间窗: Up to approximately 28 weeks
Percentage of Participants with AEs
次要结局
未报告次要终点
研究者
相似试验
Enrolling By Invitation
1 期
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral F-02-2-Na Tablets in Adult SubjectsNCT07324434Guangdong Hengqin Novagains Biopharmaceutical Co., Ltd.69
招募中
1 期
A Phase Ib Study of HW211026 Ointment in Patients With Actinic Keratosis.NCT07318675Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.40
已完成
1 期
A Study to Evaluate Single Doses of Alpha-0261 in Healthy Adult VolunteersNCT07279636AlphaMol Science Ltd. (Shanghai)55
已完成
1 期
UP-818-CC Injection in Healthy Chinese SubjectsNCT07355621EnliTISA (Shanghai) Pharmaceutical Co., Ltd.73
招募中
1 期
A First-in-human Trial of GRT7041 in Healthy ParticipantsNCT07289776Grünenthal GmbH70